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bstract
About 15% of patients diagnosed with classical Hodgkin’s lymphoma (cHL) are considered high risk with unfavorable prognosis. The
iology of the disease bears a direct relationship to its clinical course. However, some aspects of the disease are still being debated. Related
opics include origin of neoplastic cells as circulating precursor versus germinal center B cell, and disease metastasis via hematogenous routes
nd the effect of HL circulation on relapse potential and further spread of the disease. The terminally differentiated giant neoplastic Hodgkin
eed–Sternberg (HRS) cells (HRSC) have limited proliferation and lack mobility. Therefore, they are unable to penetrate epithelium. Thus, the
linical aggressiveness of HRSCs that disseminate via both lymphatic and hematogenous may be determined by their molecular composition.
his review discusses in detail the historical perspectives on scientific and clinical evidences of precursors of circulating HL cells and the
rognostic importance of these circulating cells for predicting outcome.
 2014 The Authors. Published by Elsevier Ireland Ltd. 
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.  Introduction
It has been almost 180 years since Thomas Hodgkin pre-
ented seven autopsy cases in his now famous paper “On some
orbid appearances of the absorbent glands and spleen” to
he Royal Medical and Chirurgical Society of London on
anuary 10 and 24, 1832 (the text of which was published in
he Transactions of the Medical and Chirurgical Society of
ondon) [1]. Since then, although our understanding of the
isease has increased astronomically, Hodgkin Lymphoma
HL) continues to be an enigma. For several decades, the
ellular origin of HL neoplastic cells has been debated. How-
ver, within the last two decades or so, the B cell ancestry
f the pathognomonic Hodgkin and Reed–Sternberg cells
HRSCs) has been established. The giant Reed–Sternberg
RS) cells are believed to be derived from Hodgkin’s (H)
ells by a process similar to endomitosis. Thus, H cells may
e the precursors of RS cells, which exhibit limited prolif-
ration and may be terminally differentiated. It has further
een speculated that the HRSC population is maintained
y a putative circulating precursor (CP) or circulating can-
er stem cell (CSC), a concept proposed in the late 1980s
2], but has recently received renewed attention [3], yet
emains a subject of debate. The putative CP/CSC may also,
n part, account for the spread of the disease. Although extra-
odal involvement occurs in 10–15% of all cases, metastasis
y hematogenous means remains controversial. In addition,
ome differences in the molecular composition of HRSCs
rise from genomic imbalances that resulted in either gain
r loss of gene copy number in different subsets of HL
atients [4]. In some instances, these changes seem to have
 direct impact on the relative aggressiveness of the disease
nd patient’s response to treatment [4]. For example, since
he multi-drug resistant gene MRP1 (ABCC1) confers drug
esistance, HRSCs that express MRP1 may not respond well
o ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine)
reatment [4]. In this review, we examine historical and cur-
ent materials that support the hypothesis that a putative
P maintains the HRSC population, and discuss the clini-
al and prognostic relevance of the putative precursors. We
lso examine evidence suggesting that dissemination occurs
o
i
pme; Biomarkers; Prognosis
y both lymphatic and hematogenous spread. In addition,
e discuss the mechanism(s) of chemoresistance, putative
echanism(s) of metastasis, and the prognostic significance
f extranodal disease.
. Formation  of  RS-like  cells
.1. In  vitro  formation  of  RS-like  cells  from  PBMC  of
L patients
Historically, only a handful of investigators have suspected
r expressed an interest in the idea that there was a putative CP
hat fed the population of HRSCs. Two studies provide insight
nto a putative precursor [5,6]. Zucker-Franklin and col-
eagues cultured peripheral blood mononuclear cells (PBMC)
rom HL patients on soft agar and observed, in 12 of 33
ases, colonies containing multinucleated giant cells, some of
hich were “indistinguishable” from RS cells [5]. No giant
ells formed from PBMC of NHL, mycosis fungoides, or
rom control cells, suggesting that giant cell formation from
BMC is limited to HL cases, or more specifically, a sub-
et of HL cases. The authors speculated that that “circulating
recursors of RS cells do not always find an environment hos-
itable for their development into RS cells in normal lymph
odes. It is possible that factors extrinsic to the cells may
nhibit or enhance their differentiation.” This study also sug-
ested that putative precursors may adapt well to a semi-solid
nvironment of soft agar and may differentiate into RS cells,
ndicating that the precursor may not easily differentiate in
he liquid environment [5]. Therefore, HRSCs are not likely
o be detected frequently in peripheral blood in most patients.
rom a prognostic standpoint, 8 of 12 cases that produced RS-
ike cells were diagnosed at stage I or II HL, suggesting that
utative CPs can occur even at early stages of HL [5].
In a second study demonstrating the generation of RS-
ike cells from PBMC of HL patients, the authors coculturedf HL patients with a single cell suspension of tumor cells
n a system that separated the cell populations by a micro-
orous membrane that allowed only the passage of viruses
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nd cytokines [6]. In this experimental setup, various types
f giant cells formed in the PBMC fractions, some of which
ere “indistinguishable” from RS-cells and H-cells. In all
ases, 10% of the giant cells stained for CD30, indicating
he presence of HRSCs in the mix. The remaining giant cells
ormed in this experimental set up, the CD30-negative cells,
ay be a consequence of EBV infection, since EBV can
lso induce HRSC-like morphology and phenotype on some
nfected cells (as is often seen during acute EBV infection in
nfectious mononucleosis). Also, in this same study, in situ
ybridization showed that some of the resulting giant cells
ere positive for Epstein–Barr virus (EBV+), suggesting a
ole for EBV in the transformation of the giant cells from their
ononuclear precursors. It was suggested that HL lymph
ode-derived factors may promote the formation of giant
ells, including RS-like cells, from a PBMC precursor [6].
Even though the study by Sitar et al. showed that some of
he in vitro PMBC-derived HRS-like cells were CD30+ [6],
either this study nor the study by Zucker-Franklin et al. [5]
ave provided by genetic means, evidence of a clonal relation-
hip between putative PMBC-derived HRSCs and HRSCs
f HL tumors. Vockerodt and colleagues analyzed multiple
eripheral blood (PB) and bone marrow samples from two HL
atients using a highly sensitive HRS cell clone-specific PCR
ssay, but the authors did not detect any HRS cell-specific
mplicons [7]. This suggests that HRSC clonotypic relatives
ere either infrequent or absent in these patients. Although
he study by Vockerodt et al. included only two clinical sub-
ects [7], one of its main strengths was that the subjects were
elapsed patients in whom the disease may have spread to
ultiple sites; thus, it is reasonable to speculate that dissem-
nation occurred via lymphatic and hematogenous spread.
et there was no indication of residual HRSCs in PB. In
ontrast, Jones et al. found striking similarities (e.g., similar
mmunoglobulin gene rearrangements) between putative CPs
clonotypic CD20+ B cells) in PB and HRSCs in lymph node
3]. However, this study was called into question for technical
easons [8]. For example, the fragment length analysis of V
ight chain rearrangements was considered not well suited
o determining clonal identity because the V-J joints of light
hain rearrangements showed little length variation (66% of
olyclonal V-J joints have an identical CDRIII length of 27
ase pairs) [8]. Other studies however, suggested that length
nalysis of V  light chain rearrangements is a standard and
ommonly used method for the identification of relationships
mong B-cell clones [9]. The HL cell line L1236 was raised
rom primary peripheral blood mononuclear cells isolated
rom an advanced stage cHL patients. Interestingly, L1236,
ike the circulating clonotypic CD20+ B cells [3], appears to
ave strong clonal relationship to lymph node HRSCs [10].
.2.  Generation  of  RS  cells  from  HL  cell  linesOther studies suggested that giant RS cells can be gener-
ted from precursors in HL cell lines. A sub-population of
 cells that expressed CD20 in HL cell lines gave rise to
a
glogy/Hematology 89 (2014) 404–417
RSCs in vitro [2,3]. Cells with similar immunophenotypes
ere also observed in subsets of HL patients, but these
ells failed to generate HRSCs in culture [3]. Earlier stud-
es showed that mononuclear Hodgkin cells can give rise to
ultinuclear RS cells by endomitosis [2,6,11]. The resulting
iant RS cells display limited proliferation, a characteristic
hat supports the hypothesis that the pool of HRSCs is main-
ained by putative precursors [11,12]. These studies suggest
hat putative precursors, present in cell lines and in PBMC,
an give rise to giant RS cells or RS-like cells, and also sug-
est that a precursor may be responsible for feeding the HRSC
opulation in subsets of HL cases.
.  Putative  roles  of  EBV  and  proinﬂammatory
ytokines in  transformation  events
.1.  Potential  role  of  EBV  in  the  transformation  of
utative circulating  HRS  precursors
EBV has long been suspected in the etiology of HL; how-
ver, only 40–60% of HL cases are EBV+. HRSCs in a large
ubset of patients are clonally EBV-infected as evident by the
etection of a clonal viral genome by Southern blot and in
itu hybridization [13,14], suggesting that EBV infection may
e an early event in HL pathogenesis, perhaps an event that
nvolves EBV-induced dysregulation of regulatory pathways
f a putative HRSC precursor. Proteins encoded by the EVB
enome include EBNA1, LMP1, and LMP2a. In HL, LMP1
imics CD40 ligand (a central costimulatory molecule for B
ells) binding to the CD40 receptor, thereby activating NF-B
ignaling, which is important for HRSC survival, prolifera-
ion, and escape from immune detection [15]. It is not known
f this is an early transforming event in HL, although several
tudies have shown that B cell precursors can be transformed
y EBV [16,17], some of which lead to the development of
 cell lymphomas [18]. CD30+ RS-like cells that developed
rom PBMC of HL patients were found to be EBV+, suggest-
ng a role of EBV in the transformation of a putative CP for
RSCs [6]. The transformation event may occur well before
he lymph node, because mature nodal HRSC share key fea-
ures (e.g., immunoglobulin gene rearrangements) with their
utative CPs, and also because mature HRSCs are clonally
BV infected. In some ways, transcription of EBV genes by
RSCs [19] is similar to that of nasopharyngeal carcinoma
NPC), in which both LMP1 and LMP2A induce precursors,
hich are then involved in the development of NPC [20,21].
hese observations suggest a role of EBV in the transforma-
ion of precursors of tumors cells, including HRSCs of HL.
.2.  Inﬂammation  and  the  role  of  lymph  node  in
ransformation  and  maintaining  putative  HRS  precursorInflammation of the lymph node has been considered
 contributing factor in the dysregulation that leads to
eneration of cancer stem cells (CSC) or transformation
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f tumor precursor cells. Inflamed lymph nodes and tumor
ymph nodes are known to produce multiple growth factors,
ytokines, and chemokines, which are frequently detected in
lood. These molecules exert systemic and endocrine effects
n circulating precursors. In vitro studies using autologous
L PBMC and tissues provide some insight into the role of
he HL lymph node in the formation of RS-like cells from
BMC [6,22]. Proinflammatory chemokines and cytokines
uch as IL-1 and IL-6 are found at detectable levels in serum
f subsets of HL patients, and are associated with disease
ctivity and clinical symptoms [23,24]. IL-1 appears to play
 role in partly stimulating and generating CSCs in different
ypes of solid tumors [25,26]. Lymphocytopenia and pres-
nce of B symptoms, two negative prognostic factors in HL,
ere accurate predictors of IL-6 serum levels before treat-
ent, and higher pretreatment levels of IL-6 were observed
n patients with treatment failure [27]. IL-6 signaling may be
esponsible for CSC stimulation. In breast cancer, IL-6 has
een shown to be a direct regulator of breast CSC self-renewal
28], a process that is mediated by the IL-6 receptor/GP130
omplex through activation of Stat3, which is also activated
n HL. In inflammatory cells, IL-6-mediated Stat3 signaling
electively induces a tumorigenic microenvironment [29].
tat3 activation, in turn, leads to transcriptional activation
f NF-B in inflammatory cells that secrete additional IL-6
nd IL-8, which act on tumor cells. Although breast can-
er is an epithelial tumor and HL is a lymphoid malignancy,
roinflammatory cytokine-induced transformation of puta-
ive precursors may be a shared molecular feature. Stat3 and
F-B are both constitutively active in subsets of HRSCs in
L. It will be of interest to determine if IL-6 plays a role in
he differentiation of putative CPs of HRSCs.
.  HRSCs  in  peripheral  blood
The possibility of hematogenous dissemination and the
esulting presence of HRSCs in PB were first suggested by
orothy Reed in her classic description of the morbid pathol-
gy of Hodgkin’s disease in 1902, “These giant cells occur
n great numbers in the large lymph sinuses of the gland
nd occasionally occur in blood vessels.” One of the earliest
eports of RS cells in PB came from a study of Jeanselme and
archal (1926) [30,31]. They observed RS cell emboli within
lood vessels in biopsied and postmortem organs of a patient
ho had died from Hodgkin’s disease. In addition, these giant
ells were described as being frequent in perivascular loca-
ions, and in some sections appeared to be passing through a
essel into the parenchyma [32]. Table 1 summarizes a list of
tudies that report RS cells in PB. As indicated, prognosis of
his manifestation was ominous in the pre-MOPP/ABVD era
death less than 2 years after either diagnosis or treatment),
ut appeared much improved with either MOPP or ABVD.
ne case treated with ABVD went into remission [33], and of
hose treated with MOPP, one had a CR but was treated with
econd line treatment by radiation for relapse [34]. A second
e
y
m
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ad a CR, but relapsed and was treated successfully with
hemotherapy and radiation, yet died within 3 years [35]. In
ddition, subsets of present day high risk, unfavorable HL
progressive disease, primary refractory/early relapse) still
ave a poor prognosis [36].
. Origins  of  HRSCs
.1.  Cellular  origin  of  HRSCs
There appears to be two types of morphologically dis-
inct but immunophenotypically similar neoplastic cells
hat are characteristic of HL: the mononuclear Hodgkin’s
ells and the multinuclear Reed–Sternberg cells, collectively
nown as HRSCs. Molecular analysis of microdissected
RSCs from solid cHL tumors showed that these cells har-
ored clonal immunoglobulin gene rearrangements similar
o that of B cells, suggesting a B-cell ancestry [37,38].
n the majority of cases, the immunoglobulin gene rear-
angements showed somatic hypermutation, suggesting that
he HRSCs arose from germinal center or post-germinal
enter B cells. In some instances, cHL showed loss of func-
ion mutations, including nonsense mutations, in their V
enes [37]. Normally, cells that inherit such crippling muta-
ions will rapidly undergo programmed cell death. However,
ost-germinal center HRSCs are able to escape apopto-
is, perhaps via an advantageous mechanism(s) inherited
rom their precursors. In very rare instances, cHL contains
RSCs that are descendants of T cells as they (the HRSCs)
arry clonal T cell receptor gene rearrangements [39,40].
anifestation of HRSCs has been reported for other hemato-
ogical malignancies including peripheral T cell lymphomas
41,42], multiple myeloma (MM) [43,44], chronic lympho-
ytic leukemia/small lymphocytic lymphoma (CLL/SLL)
45,46], and follicular lymphoma [47,48]. And at least one
tudy reported the coexistence of HRSCs with mantle cell
ymphoma (MCL) tumor cells in MCL [49]. It will be inter-
sting to determine whether HRSCs in different lymphomas
re lineal descendants of common precursors, and whether
he characteristic(s) of each variant is determined by the
icroenvironment of each lymphoma subtype.
.2.  Loss  of  B cell  programming  by  HRSCs
HRSCs rarely express immunoglobulin or other B-cell
arkers [50–52]. Occasionally, their failure to express
mmunoglobulin appears to be a consequence of crippling
utations in immunoglobulin genes. However, such crip-
ling mutations occur only in a minority of HL cases, and
sually only in those that are EBV-positive [52]. A lack of
unctional immunoglobulin (and other B cell-specific gene
xpression) has been attributed to epigenetic (e.g., demeth-
lation) silencing of the immunoglobulin heavy chain and/or
aster transcription factors [53,54]. One consequence of epi-
enetic silencing is the upregulation of NOTCH1, a negative
408 R. Gharbaran et al. / Critical Reviews in Oncology/Hematology 89 (2014) 404–417
Table 1
Studies reporting HRSCs or HRS-like cells in peripheral blood.
Reference(s) Gender Age Stage and subtype Treatment(s) and outcome
Miyoshi (2005) [157] M 69 2× alternating CVPP versus DPVD; NR; dead <1 year
Milosevic et al. (2003) [33] M 33 IV/V NS-cHL 9× ABVD; remission
Wolf et al. (1996) [158] F 31 IA, MC-cHL Radiation therapy (40 Gy); remission but relapsed
Cavalli et al. (1981) [34] F 33 LD-cHL 6× MOPP→CR; 6× BCN/BCVPP+ radiation for rel.
Riccardi et al. (1980) and Malfitano
et al. (1980) [35,159]
F 35 IIIB, LD-cHL MOPP→CR; rel. succ. w/C + RT; death <3 years
M 27 IIsA, LD-cHL COPP→CR; rel. td w/CVPP-BCNU, ABVD, MOPP
Sinks and Clein (1966) [160] F 78 N/A NM; death <1 year
Bouroncle et al. (1966) [32] N/A N/A N/A 25/135 patients showed RS cells in PB (18 patients showed RS
cells 1–4 months before death; 4 patients achieve remission for
1.4–3 years; 3 survive >3 years)
Scheerer et al. (1964) [161] M 47 N/A X-ray therapy→NR; NM→ reduced skin lesion;
cyclophosphamide→improve symptoms; death from
staphylococcal pneumonitis
Libansky et al. (1962) [162] F 18 N/A NM + P→improve; rel.; death < 6months
Varadi (1960) [31] M 58 N/A Penicillin; death <8 days after admission
F 69 N/A Penicillin, folic acid, transfusion; death by accident
Ludman and Spear (1957) [163] M 27 N/A NM→brief R; death <1 year
Two other studies (Chrobak and Horacek (1960) and Capron and Menne (1969)) were not cited.
Abbreviations: ABVD, Adriamycin, bleomycin, vinblastine, and dacarbazine; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea, BCVPP, BCNU + CVPP; C + RT,
chemo + radiotherapy; cHL, classical Hodgkin’s lymphoma; COPP, cyclophosphamide, vincristine sulfate (Oncovin), procarbazine, prednisone; CR, complete
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ymphocyte depleted; MC, Mix cellularity; MOPP, Mustargen Oncovin Proc
S, nodular sclerosing; R, remission; Rel., relapse; td, treated; succ, succes
egulator of the B cell program [55], and also upregu-
ation of non-B cell lineage proteins [56]. Demethylation
tudies of cultured RS cells showed that the B cell program-
ing is irreversible [57]. In spite of this, subsets of HRSCs
etain some aspects of a B cell signature, expressing CD20,
DC1/CD138, or CD79a [58–62]. There is not a clear consen-
us on the prognostic significance of these molecules in HL.
onetheless, differences in the B cell signature of HRSCs
ay influence the behavior of these tumor cells, and there-
ore, may have prognostic importance.
.  Chemoresistance
.1.  Mechanism(s)  of  chemoresistance:  involvement  of
rimary HRSCs  and  putative  precursors
Chemoresistance, an increasing problem with conven-
ional therapy for multiple cancer types, may be due to
rimary tumor cells or CPs that develop resistance to thera-
eutic drugs. Either way, the responsible cells can be regarded
s circulating tumor cells. HL may be one such neoplasm.
esistance to the doxorubicin used in the ABVD regimen
as been demonstrated in HL cell lines [4], other human
ymphoma cells [63], and in cases of multiple myeloma
nd non-Hodgkin’s lymphoma [64]. Increases in the copy
umber of the doxorubicin-resistance gene ABCC1 were
requently detected in HRSCs in pre-treated and relapsed
iopsies of patients who failed primary treatment [4]. In
nother study, 0.2–6.5% of cells with an HRS-like phenotype
resent in primary HL tumors showed the ability to increase
fflux of Hoechst 33342 dye, were resistant to gemcitabine (a
a
w; DPVD, doxorubicin, bleommycin, vincristine, and dexamethasone; LD,
e Prednisone; N/A, not available; NM, nitrogen mustard; NR, no response;
ommonly used drug for the treatment of radioresistant-HL),
nd expressed other multidrug resistance genes including
BCG2 and MDR1 (ABCB1, P-glycoprotein, pgp) [65].
verexpression of ABCB1 by HRSCs of HL is associated
ith primary progressive disease, presence of B symptoms,
nd shortened disease-free survival [66]. These observations
uggest that subsets of HRSCs employ several different mul-
idrug resistance proteins to overcome the effects of cytotoxic
rugs.
Other genes that are upregulated by HRSCs follow-
ng exposure to cisplatin, etoposide, or melphalan include
he cytokine receptors IL5RA and IL13RA1, antigen pre-
enting cell markers CD40 and CD80, and genes with known
ssociations with chemoresistance such as myristoylated
lanine-rich protein kinase C substrate and PRAME (prefer-
ntially expressed antigen in melanoma) [67]. A number of
ecent clinical trials targeting these molecules or their cognate
athways resulted in only modest improvement in patient out-
ome, perhaps because of exposure to heavy pre-treatment.
or example, in a phase II clinical trial, the anti-CD80
onoclonal antibody Galiximab was administered to 30
adioresistant-HL patients resulted in a 6.9% overall response
ate [68].
.  Metastasis
.1.  Molecular  mechanism(s)  of  metastasis  by  HRSCs
nd their  putative  precursorsAlthough HRSCs are rarely observed in PBMCs, the
natomic view of predictable, contiguous spread is consistent
ith lymphatic or hematogenous dissemination. However,
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he molecular mechanism(s) by which HRSCs escape the
umor microenvironment is not clear, although subsets of
hese cells express genes known to promote aggressive tumor
etastases: FGF2, SDC1, TGF1, MMP2, MMP9. From
 clinical standpoint, MMP9 is associated with an adverse
utcome [69]; elevated serum SDC1 has been reported for
ubsets of HL patients [70], and high levels of serum FGF2
n HL is associated with an increased erythrocyte sedimenta-
ion rate, a factor associated with poor prognosis [71]. TGF1
s expressed by HRSCs and other cell types, and it has been
etected in urine of patients with active disease [72]. The par-
icular combination of these markers upregulated by subsets
f HRSCs may determine their metastatic aggressiveness. In
yeloma and other cancers, shedding of SDC1 can facili-
ate growth, angiogenesis, and metastasis [73–76]. Shedding
s in part driven by heparinase, which influences syndecan-
 localization by upregulating expression of enzymes that
ccelerate its shedding from the cell surface. Elevated levels
f heparinase observed in the blood of HL patients including
hildren [77,78] may be responsible for shedding of SDC1
rom the surface of malignant HRSCs, resulting in the high
evels of soluble SDC1 observed in serum of HL patients [70].
s a consequence, the shedding may promote the escape of
RSCs from their microenvironment.
These metastatic molecules may also promote metastatic
pread of HRSCs via activation of the NF-B pathway. In
L, proliferation and survival of HRSCs is promoted by
onstitutive activity of the NF-B pathway [79]. Indeed,
everal studies have focused on the requirement of the NF-
B signaling pathway for MMP-9 expression [80–82]. The
F-B pathway is also important in tumor invasion and
t
t
p
ig. 1. A. NF-B receives multiple signaling from FGF2, SDC1, and TGF1 to u
atrix collagen resulting in cellular metastasis and invasion. B. Activation signali
ature of subsets of HRS, potentially resulting in extranodal disease, circulating HLlogy/Hematology 89 (2014) 404–417 409
etastases in multiple cancer types. It has been reported
hat MMP-9 expression is regulated transcriptionally through
F-B elements within the MMP-9  gene [83]. Using an ade-
ovirus that overexpressed the inhibitory subunit IB, it was
ound that NF-B activation was an absolute requirement for
pregulation of MMP-9. Although not demonstrated in hema-
ological malignancies, constitutive activity of NF-B and
pregulation of MMP9 were found to be strongly influenced
y the upregulation of SDC1 in endometrial cancer, result-
ng in increased cancer cell proliferation and invasiveness
84]. NF-B was also shown to participate in upregulation of
DC1 in malignant glioma cells [85]. These studies suggest
hat SDC1 and NF-B are involved in a feedback loop, pos-
ibly driving the expression of downstream targets including
MP9 [84,85].
The expression of SDC1 may also be under the influ-
nce of FGF2. A cis-acting FGF2-inducible response element
FiRE) located upstream of the SDC1 gene [86] may allow
GF-2-induced upregulation of SDC1 in NIH3T3 fibroblasts
87,88]. A further transcriptional role of either or both FGF2
nd SDC1 has been suggested by their nuclear localization
76,89–91]. In addition, the overexpression of nuclear SDC1
esulted in increased accumulation of nuclear FGF2 in mes-
nchymal tumor cells [89]. As well, LMP-1 induces release
f FGF2, which is involved in activation of NK-B signaling
92]. In addition, in vitro studies showed that TGF1 and
GF2 together promote SDC1 upregulation and its shed-
ing from the surface of 3T3 cells [87]. Thus, it appears
hat TGF1 and FGF2 activate SDC1 expression, which in
urn drives the NF-B pathway to upregulate MMP9, thereby
romoting cellular invasion and metastasis (Fig. 1A). In
pregulate MMP9, which subsequently causes degradation of extracellular
ng by EBV+, NF-B, TGF, MMP, and MDR contribute to the aggressive
 tumor cells, and poor outcome.
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Fig. 2. Alternative view of HL metastasis. Putative transforming event
involves EBV and inflammation. The resulting putative circulating precur-
sors home into the “ideal niche”, in most instances the lymph node, and to
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f lesser extent, other organs (e.g., CNS, liver, lung, etc.). The “ideal niche”
romotes differentiation of precursors into HRS cells.
ddition, multiple signaling involving some of these
olecules in aggressive HRSCs may be responsible for extra-
odal disease, and poor clinical outcome in HL (Fig. 1B).
The classic metastatic marker in many cancer types,
D44, is also upregulated in HL [93], and plays an impor-
ant role in hematogenous dissemination of non-Hodgkin’s
ymphoma [94]. Serum levels of CD44 are elevated in
ntreated HL patients. In patients with complete response,
D44 decreases to levels comparable to that in normal con-
rols, but remains increased in those with progressive disease
95]. In addition, the expression of CD44 splice variant v10
y large numbers of HRSCs is associated with aggressive
ehavior and high risk of relapse in nodular sclerosing HL
96]. The overexpression of CD44 in HL may be related to
emethylation [97].
An alternative view of HL metastasis is related to putative
irculating HRSC precursors. Recent studies have implied a
ole for the microenvironment, the so-called “premetastatic
iche,” in determining the pattern of metastatic spread [98].
he premetastatic niche in extranodal sites may permit the
oming of CPs, which subsequently develop into mature
RSCs within a permissive niche that favors their develop-
ent and survival. In other neoplasms, tumor precursor cells
re known to release exosomes with the potential to pro-
ote the formation of a premetastatic niche [99], a process
hat is also CD44-dependent [100]. Although no direct data
n exosome involvement in HL is available, the manner by
hich HRSCs secrete FGF2, which lacks a secretion signal
equence, may occur via exosome release [101]. In addition,
ro-inflammatory cytokines [23] and EBV [6] may be impor-
ant players in the early stages of a multi-step transformation
vent of these putative precursors. Fig. 2 summarizes HL
etastasis by putative CPs for HRSCs. The occurrence of
utative CPs that feed the occult tumor cell population implies
hat metastatic spread is random. However, the evidence is
verwhelming that spread of the disease is contiguous, the
xpectation of which is integral to the current staging system.
irect evidence implicating contributions of a premetastatic
iche in HL pathogenesis may be hindered by the rarity of the
l
a
cig. 3. Contiguous metastasis. HRSCs with metastatic potential exit the
umor lymph node via efferent lymph vessel, migrating predictably to the
ext node.
utative HRS precursors and the difficulty of growing these
ells in culture [3]. However, immunohistochemical analy-
is of tissue biopsies from primary and secondary tumors, as
ell as primary extranodal HL tumors, may provide clues
egarding the nature of the premetastatic niche.
.  Routes  of  dissemination
.1.  Lymphatic  and  hematogenous  spread
Early work resulted in a better understanding of the
haracteristic nonrandom and predictable spread of HL via
ymphatic channels to contiguous lymph node chains and
ther lymphoreticular structures [102,103]. However, spread
o distant tissues is expected to involve either lymphatic or
ematogenous routes. Fig. 3 summarizes the routes of spread
f HL. Once a migratory cell has detached from its primary
umor site, it may intravasate into blood vessels or lymphatics.
ither route of dissemination can lead to venous circulation,
s lymphatics drain into blood, most commonly through the
eft lymphatic duct (thoracic duct) or the right lymphatic duct,
nd subsequently into the subclavian veins. Along the way,
ymphatic fluid is filtered through lymph nodes, a process
hat will normally clear abnormal cells such as tumor cells
rom the circulation. When immunity is reduced, as occurs in
ymphocytopenia, a negative prognostic factor in HL [104],
ggressive HRSCs may metastasize more rapidly. The exact
ause of lymphocytopenia in HL is not known, but it may be
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 consequence of immunosuppressive cytokines produce by
L tumor cells.
.  Prognosis  of  extranodal  disease
.1.  Prognostic  signiﬁcance  of  extranodal  sites
ommonly involved  in  primary  nodal  HL
Extranodal HL can arise either by dissemination from a
rimary tumor site, or as a primary tumor in non-nodal, non-
ymphatic tissue. Extranodal invasion of adjacent and distant
issues via hematogenous spread occurs in 5–10% of HL
ases [105]. Roughly 6–12% of cases of lung parenchyma
nvolve spread of HL in origin [106–109]. Lung parenchyma
nvolvement may or may not involve direct extension of a
arge mediastinal mass in the lungs. Patients with limited
tage disease having a large mediastinal mass that extends
nto the lung parenchyma exhibit inferior disease-free and
otal survival rates after treatment with radiation alone [110].
leural effusion is relatively common at presentation [109]
ccurring in about 13% of cases [111]. The main cause
f effusion in HL, which may be unilateral or bilateral, is
bstruction of lymphatic drainage by enlarged mediastinal
ymph nodes. Although pleural effusion does not appear
o be of significance in HL prognosis, frequent analysis of
leural fluid for the presence of HRSCs may be useful in
ollow-up to identify relapse [112]. Heart and pericardial
ffusion in HL is estimated to occur in 5–18% of cases
105,113–115]. This may be partly due to retrograde lym-
hatic spread, hematogenous spread, or direct extension from
n intrathoracic tumor mass. Heart involvement, which rep-
esents a late manifestation of the disease and indicates a poor
rognosis, is asymptomatic and in most cases is determined
nly at autopsy [105,113]. However, because of improved
maging techniques for early detection of pericardial effu-
ion or heart failure by computed tomography, pediatric
atients with imaging data experienced greater long term
urvival than the group without imaging data and resumed
ormal cardiac function after chemotherapy [114,116]. Chest
all involvement accounts for 6.4% of cases [111,117,118]
ncluding pediatric cases [117]. Early stage (I and II) HL
atients with chest wall invasion exhibited inferior outcomes
progressive disease, relapse, inferior disease-free survival,
orse cause-specific survival, and shorter overall survival)
118].
Early studies on staging laparotomy showed that spleen
s infiltrated in about 30–40% of patients at presentation
119–121], most of which are marked by splenomegaly
106,119]. However, diagnostic laparotomy with splenec-
omy in HL has been rarely performed in recent years due to
oncerns over impact on survival, delay in onset of treatment,
nd long-term consequences of splenectomy [122,123]. Nev-
rtheless, spleen involvement is usually more frequent in
dvanced stage disease, and represents a poor prognostic
actor [124]. The involvement of spleen in HL increases
m
r
l
rlogy/Hematology 89 (2014) 404–417 411
he likelihood of hepatic involvement [120], as the splenic
nd common hepatic arteries share a common hematoge-
ous route. Hepatic involvement at presentation occurs in
–20% of patients [106,119,125]. Hepatic involvement, like
plenic involvement, is an indicator of adverse prognosis
124,126–129]. In extremely rare cases, HL is involved in
he gastrointestinal tract [125,130] and the genitourinary sys-
em [125]. Gastrointestinal involvement occurs mostly in late
tage (IV) disease and may represent an adverse prognostic
actor in disseminated HL [130]. Although data for differ-
nt treatment options for gastrointestinal disseminated HL
re not available, in primary gastrointestinal HL, either radi-
al gastrectomy or multi-agent chemotherapy resulted in no
ecurrent disease on follow-up [131,132], suggesting that pri-
ary GI HL may have a better prognosis than gastrointestinal
isseminated HL. There has been one report of testicular
nd epididymal involvement with stage IV-A; the patient
emained disease-free three years after diagnosis and treat-
ent with combination therapy, indicating a good prognosis
133].
The incidence of skeletal Hodgkin’s disease varies from 9
o 14% during the course of the disease but reaches as much
s 30–50% at post mortem [134]. Skeletal involvement may
nclude invasion of bone marrow and osseous tissue by tumor
ells. About 5–38% of patients will develop bone marrow
nvolvement during the course of the disease [135,136] but
nly 1–4% will exhibit bone marrow involvement at presenta-
ion [119,137,138]. Bone marrow involvement in most cases
s considered a late stage manifestation, and is associated
ith poor prognosis [136,139]. Involvement of osseous tissue
ay arise from either contiguous spread or via hematogenous
issemination [119,138].
Integumentary or cutaneous involvement is also extremely
are, occurring in 0.5–3.4% of HL patients [140,141].
he mechanism(s) of skin involvement in HL remains
nknown; however, possibilities include retrograde lym-
hatic spread from tumor-involved lymph nodes, direct
xtension into skin by tumor cells in underlying lymph nodes,
r hematogenous spread [140,141]. Cutaneous involvement
s usually associated with diffuse lymphadenopathy, late
tage disease (typically IV), and poor prognosis [140–143],
lthough a good response to standard therapy has been
eported [144].
Central nervous system involvement of HL (CNS-HL)
s an uncommon but well-known complication of systemic
L, occurring in 0.2–0.5% of all cases in advanced stages
145–147]. Within the CNS, intracranial metastases, metas-
ases to the epidural space of the spinal cord, which causes
ompression of the spinal root, metastatic leptomeningeal
isease, and intramedullary spinal cord metastases are most
ommonly seen. Hematogenous spread is the putative mech-
nism of dissemination of HL to the CNS [148]. Although
ost early studies indicate a poor prognosis of CNS-HL, a
ecent study showed that complete remission and improved
ong term survival can be achieved with chemotherapy and
adiation [149].
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0.  Opportunity  for  brentuximab  and  rituximab  in
reatment  of  cHL
Three populations of cells in HL are potential targets for
herapy: H and RS cells, which express CD30, and CD20+
lonotypic B cells, which may represent putative CPs of
RSCs. CD30+ HRSCs have been discussed at length by
any authors. CD20+ clonotypic B cells and their putative
ole in HL pathology have only recently come to attention.
s indicated, CD20+ clonotypic B cells are postulated to be
SCs that feed the HRSC population [3]. However, the exist-
nce of CSCs is still a hotly debated issue in multiple cancer
ypes [150] including HL [8]. Should more solid evidence
rove the existence of circulating clonotypic CD20+ B cells
n cHL, they may become potential targets for anti-CD20
herapy. A phase II clinical trial assessing the combination of
ituximab (which targets CD20) plus ABVD on the behav-
or of CD20+ clonotypic B cells in stage IIB-IV HL patients
esulted in actuarial 3-year event-free and overall survival
ates of 83% and 98%, respectively [151]. EBV copy num-
er in plasma fell dramatically during cycle 1 in patients
ith EBV+ tumors [151]. In this same study, the authors also
ound that the persistence of detectable circulating clonotypic
 cells was associated with a greater relapse frequency [151].
n addition, the authors reported that the levels of clonotypic
D20+ B cells became undetectable in a subset of patients
fter Rituximab-ABVD treatment [151]. However, the biol-
gy and the role of circulating clonotypic CD20+ B cells
n HL pathogenesis are not completely understood. Prior to
he study by Kasamon et al. [151], two independent studies
ound that peritumoral CD20-expressing background B cells
ere associated with favorable outcome [152,153]. However,
nti-CD20 antibody therapy with rituximab has resulted in
bjective responses in a subgroup of relapsed cHL patients
154]. The response to rituximab therapy may be due to a
irect effect on subsets of HRSCs that occasionally express
D20 [61]. An alternative but simultaneous effect of ritux-
mab therapy may be the eradication of reactive CD20+ B
ells from the tumor microenvironment, a point that seems
onsistent with one of the main findings of the study by Kasa-
on et al. (decreased circulating clonotypic CD20+ B cells)
151], despite differences in microenvironment.
Rituximab has also exhibited success in the treatment
ther neoplasms [155]. However, the Rituximab plus ABVD
ombination, although well tolerated by HL patients [151],
ay result in more side effects and greater risk of long
erm complications than either brentuximab vedotin or rit-
ximab alone. A combination of brentuximab, vedotin, and
ituximab, however, may produce superior or comparable
utcomes as ABVD, but with less severe side effects. The
ain advantage of this combination is that both CD20+ and
D30+ malignant cells are targeted, thus removing larger
umbers of occult tumor cells, along their putative CPs.
his treatment may especially benefit HL patients in whom
he HRSCs express multidrug resistance genes, a group of
atients who will most likely experience primary treatment
fi
l
plogy/Hematology 89 (2014) 404–417
ailure with a conventional therapeutic regimen. Success
f this protocol, however, will depend on identification of
atients before conventional treatment, because heavily pre-
reated patients who fail frontline therapy continue to do
oorly with alternative/second line treatments.
1.  Prognostic  signiﬁcance  of  a  putative  precursor
or HRSCs
Currently, there is strong suspicion that circulating CSCs
r circulating precursor cells are largely responsible for
efractory and relapsing disease in both solid and liquid
umors. The persistence of circulating clonotypic CD20+
 cells presumed to include putative CPs for HRSCs [3]
as been shown to be associated with greater frequency of
elapse in rituximab-ABVD treated HL patients [151]. The
rug resistant HL cell line KM-H2 contains a similar subset
f cells, but these cells appear to extrude Hoechst stain in
 manner similar to the expulsion of drugs by drug resistant
ells. Although KM-H2 and primary HRSCs of subsets of HL
atients who experience primary treatment failure harbor ele-
ated expression of drug resistant genes [4,156], it is not clear
f the clonotypic CD20+ B cells also overexpress such genes.
his information may be important in developing alternative
herapies for relapsing and refractory HL, as most current
reatments for high risk HL continue to have little impact.
2.  Technical  limitations  and  considerations  for
nalysis of  putative  HRS  precursors  in  vitro
The putative HRSC precursors isolated from HL patients
re difficult to culture in the laboratory setting [3]. Since RS-
ike cells can develop from patient PBMCs when cocultured
ith autologous HL lymph node extract [6], it may be useful
o use a similar system to study the in vitro behavior putative
RS precursors.
3.  Conclusion
The evidence indicates that HL dissemination can occur
ither by lymphatic or hematogenous means, resulting in
xtranodal disease and ultimately poor prognosis. There
ppear to be three occult cells that are responsible: H cells,
hich are considered more aggressive, RS cells, which have
imited proliferation, and putative circulating precursors that
eed the HRSC population. The molecular phenotypes of
ubsets of HRSCs may determine prognosis. Putative circu-
ating precursor cells of HL or of other tumor types represent
n ominous indicator, and are frequently associated with
hemoresistance, treatment failure, and relapse. Genetic pro-
ling of putative HRSC precursors and similar cells in other
ymphomas should provide insight into common origins, and
erhaps will lead to better treatment options.
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